Who is sponsoring NCT05447221?

NCT05447221 is sponsored by Shandong University.

What drugs are being tested in NCT05447221?

Interventions in NCT05447221: The diagnosis of Artificial Intelligence and pathologists.

What condition does NCT05447221 study?

NCT05447221 studies Gastric Intestinal Metaplasia, Artificial Intelligence, Pathology, Gastric Cancer.

Is NCT05447221 still recruiting?

NCT05447221 is currently status unknown. Last updated 6 September 2023.

Last reviewed 2023-09-06 · How we verify

NCT05447221

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Automatic Evaluation of the Severity of Gastric Intestinal Metaplasia With Pathology Artificial Intelligence Diagnosis System

Status unknown Last updated 6 September 2023

What this trial tests

trial testing The diagnosis of Artificial Intelligence and pathologists in Gastric Intestinal Metaplasia in 150 participants. Status unknown.

Timeline

1 August 2022

Primary endpoint
31 December 2023

31 December 2023

Quick facts

Lead sponsor	Shandong University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	150
Start date	1 August 2022
Primary completion	31 December 2023
Estimated completion	31 December 2023
Sites	1 location across China

Drugs / interventions tested

The diagnosis of Artificial Intelligence and pathologists

Conditions studied

Gastric Intestinal Metaplasia — all drugs for Gastric Intestinal Metaplasia →
Artificial Intelligence — all drugs for Artificial Intelligence →
Pathology — all drugs for Pathology →
Gastric Cancer — all drugs for Gastric Cancer →

Sponsor

Shandong University

Who can join

Adults 40 to 75, any sex, with Gastric Intestinal Metaplasia or Artificial Intelligence. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The OLGIM staging system is highly recommended for a comprehensive assessment of GIM severity to evaluate patients' gastric cancer risk. However, its need to take at least 4 biopsies is not clinically feasible due to a serious shortage of pathologists compared with the large number of gastric cancer screening population. We plan to develop a Digital Pathology artificial intelligence diagnosis system (DPAIDS), to automatically identify tumor areas in whole slide images(WSI) and quickly and accurately quantify the severity of intestinal metaplasia according to the proportion of intestinal metaplasia areas.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Current Role of Artificial Intelligence in the Management of Gastric Cancer.
Liatsou E, Driva TS, Vergadis C, Sakellariou S, et al · · 2025 · PMID 41462951 · DOI 10.3390/biomedicines13122939

Verify or expand the search:

Other recruiting trials for Gastric Intestinal Metaplasia

Currently open trials in the same condition.

NCT06590454 — REVerse Intestinal Metaplasia in the Stomach (REVISE) · Phase 2 · recruiting
NCT06610266 — Efficacy and Safety of Weifuchun Tablet in Reversing Gastric Intestinal Metaplasia · Phase 4 · recruiting
NCT06610760 — Efficacy and Safety of Ursodeoxycholic Acid in Reversing Gastric Intestinal Metaplasia · Phase 4 · recruiting
NCT06370143 — A Study Collecting Health Information to Understand and Prevent Gastric Cancer · recruiting
NCT05657080 — Cytosponge for Gastric Intestinal Metaplasia · recruiting

Other Shandong University trials

Trials by the same sponsor.

NCT07288346 — Effect of Predictive Model on Double-Balloon Enteroscopy · NA · recruiting
NCT07325344 — Active Locomotion of Magnetically Controlled Capsule Endoscopy in the Small Bowel: A Feasibility Study · NA · recruiting
NCT07319312 — Evaluating the Effect of Nurse-Led Stroke Transitional Care in Tanzania · recruiting
NCT07391787 — Low-acid Contrast Media for Preventing Post ERCP Pancreatitis · completed
NCT07066059 — Study on the Efficacy and Safety of Shouhui Tongbian Capsules in Protecting Intestine During the Perioperative Period · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05447221 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shandong University
Last refreshed: 6 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05447221.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing